This is a working overview of Ac-SDKP, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2025-10-18. Anything still debated is marked as such rather than presented as settled.
Interest in the fragment grew during the 1990s and 2000s, when it moved from laboratory work into sports and supplement markets. Anti-doping bodies added thymosin beta-4 fragments to prohibited lists, and a small number of adverse analytical findings have been reported in competition testing. Published controlled human trials remain scarce. Most mechanistic evidence comes from cell culture and animal models, and those studies examine endpoints such as cell migration, wound closure and inflammation markers. That evidence supports research interest but does not establish clinical benefit, and broad regenerative claims should be read as unverified.
TB-500 is a short synthetic peptide sold under a trade name rather than a systematic chemical name. Suppliers usually describe it as a fragment of thymosin beta-4 and ship it as a lyophilised powder intended for laboratory use. Because the label is commercial, the exact sequence attributed to it is not fully consistent across catalogues, and some listings present a seven-residue peptide while others describe related fragments of similar length. It is not an approved medicine in any major jurisdiction, and it is handled as a research chemical.
Identity and purity are checked with chromatographic and mass spectrometric methods. Reverse-phase high-performance liquid chromatography separates the peptide from related impurities, while mass spectrometry confirms the expected molecular mass. A certificate of analysis may report a purity percentage, but the laboratory should still verify the material independently. Common quality concerns include truncated sequences, deamidation, oxidation, and residual solvents from synthesis. Because TB-500 is short, some impurities can differ from the target by only a few mass units.
Reconstitution practices affect downstream measurements. The dry powder is typically dissolved in sterile water or a suitable aqueous buffer, then mixed gently rather than vortexed at high speed. Visible particles or cloudiness suggest incomplete dissolution or contamination and should be investigated. For long-term storage, aliquots should be labeled with concentration, solvent, and date. Open questions include how different buffers alter peptide conformation and whether specific container materials adsorb the peptide. Those variables can change apparent concentration in assays even when the chemical identity is correct.
Lyophilized TB-500 is hygroscopic and should be kept dry before use. The usual storage recommendation for the solid is -20 °C, protected from light and moisture. Once dissolved, the peptide is less stable, and repeated freeze-thaw cycles can promote aggregation or degradation. Laboratories often divide a reconstituted solution into single-use aliquots and store them at -80 °C. Exact stability limits depend on buffer, pH, and concentration, so published data do not define a single universal condition.
| Property | Value | Notes |
|---|---|---|
| Name type | Commercial trade name | Not a systematic chemical identifier |
| Parent peptide | Thymosin beta-4 | 43-residue natural peptide |
| Common fragment sequence | LKKTETQ | Maps to part of the actin-binding region |
| Molecular size class | Roughly 0.8-1.0 kDa | Depends on exact fragment and terminal modification |
| Regulatory status | Prohibited in sport | Grouped with peptide hormones in many frameworks |
The compound circulates in the literature as a research reagent rather than an approved therapeutic. Regulatory agencies in several countries have not authorized it for medical use, and sporting bodies list related thymosin beta-4 peptides among prohibited substances. Suppliers typically market it with a purity figure and a certificate of analysis, while peer-reviewed clinical reports remain sparse. Discussions therefore often separate laboratory findings from anecdotal reports, and reviewers tend to note the small size and methodological limits of the available studies.
TB-500 refers to a synthetic peptide fragment derived from the actin-binding region of thymosin beta-4, a protein present in most mammalian cells. The full protein contains forty-three amino acids, while the commonly sold fragment is a much shorter acetylated sequence, often cited as LKKTETQ. The fragment retains part of the actin-binding motif but lacks the remainder of the parent protein. Material sold under this name is usually lyophilized powder intended for laboratory research, and it is not a finished pharmaceutical product.
Animal work has examined the peptide in models of cardiac injury, skin wounding, and corneal repair, with reported outcomes covering cell migration, inflammatory cell influx, and tissue remodeling. Several of those experiments used the full-length protein or longer fragments instead of the seven-residue sequence, which makes direct comparison between reports difficult. Results are generally described as tissue-dependent, and effect sizes vary considerably across laboratories. Independent replication is uneven, so the overall picture is incomplete rather than settled.
Controlled human trials of the short fragment are scarce. Much of what appears in review articles is extrapolated from animal models or from studies of the parent protein, and literature searches return a larger body of cardiac and ophthalmic work on thymosin beta-4 than on the abbreviated peptide. Regulatory treatment differs by jurisdiction, and in several countries the material is handled as a research chemical rather than an approved therapeutic. Statements about human benefit should be read as provisional.
TB-500 is a laboratory label applied to a short synthetic peptide that is widely described as a fragment of thymosin beta-4, an actin-binding protein present in most mammalian cells. Suppliers and review articles usually present TB-500 as the N-terminal region of that protein, but the exact sequence attached to the name is not consistent across sources. Some product descriptions list a seven-residue chain; others use the label loosely for the parent protein itself. Because of that variation, any technical discussion of TB-500 needs to state which sequence is meant.
Thymosin beta-4 contains 43 amino acids and has a reported molecular mass near 4963 Da. The short fragment most often associated with the TB-500 label, an acetylated chain beginning LKKTETQ, has a reported mass near 889 Da, so the two are easily separated in analytical work. Mass spectrometry and amino acid analysis can confirm which material is present in a given sample. Statements treating TB-500 and thymosin beta-4 as interchangeable are therefore imprecise, even though the two appear together in much of the same literature.
==== MeSH D12.776.575.750.500 – mitochondrial adp, atp translocases ==== MeSH D12.776.575.750.500.100 – adenine nucleotide translocator 1 MeSH D12.776.575.750.500.200 – adenine nucleotide translocator 2 MeSH D12.776.575.750.500.300 – adenine nucleotide translocator 3
==== DOx ==== The DOx family of psychedelics are also known as "substituted amphetamines" as they contain the amphetamine backbone but are substituted on the benzene ring. This gives rise to serotonin agonists similar to the 2C-X class but more resistant to elimination in the body.
Pharming, a portmanteau of farming and pharmaceutical, refers to the use of genetic engineering to insert genes that code for useful pharmaceuticals into host animals or plants that would otherwise not express those genes, thus creating a genetically modified organism (GMO). Pharming is also known as molecular farming, molecular pharming, or biopharming. The products of pharming are recombinant proteins or their metabolic products. Recombinant proteins are most commonly produced using bacteria or yeast in a bioreactor, but pharming offers the advantage to the producer that it does not require expensive infrastructure, and production capacity can be quickly scaled to meet demand, at greatly reduced cost.
where the solubility product for [Ca2+][CO2−3] is given as anywhere from Ksp = 3.7×10−9 to Ksp = 8.7×10−9 at 25 °C, depending upon the data source. What the equation means is that the product of molar concentration of calcium ions (moles of dissolved Ca2+ per liter of solution) with the molar concentration of dissolved CO2−3 cannot exceed the value of Ksp. This seemingly simple solubility equation, however, must be taken along with the more complicated equilibrium of carbon dioxide with water (see carbonic acid). Some of the CO2−3 combines with H+ in the solution according to
Sources: en.wikipedia.org
=== Other === Photon correlation spectroscopy/Dynamic light scattering (DLS) Terahertz spectroscopy (THz) Electron paramagnetic/spin resonance (EPR, ESR) Small-angle neutron scattering (SANS) Rutherford backscattering spectrometry (RBS) Spatially resolved acoustic spectroscopy (SRAS)
Vericiguat, sold under the brand name Verquvo, is a medication used to reduce the risk of cardiovascular death and hospitalization in certain patients with heart failure after a recent acute decompensation event. It is taken by mouth. Vericiguat is a soluble guanylate cyclase (sGC) stimulator. Common side effects include low blood pressure and low red cell count (anemia). It was approved for medical use in the United States in January 2021, and for use in the European Union in July 2021.
In 1956, Tsung-Dao Lee and Chen Ning Yang noticed that there was no evidence that parity was conserved in weak interactions, and so they postulated that this symmetry may not be preserved by the weak force. They sketched the design for an experiment for testing conservation of parity in the laboratory. Later that year, Chien-Shiung Wu and coworkers showed experimentally that an asymmetrical beta emission from 60Co proved that parity is not conserved in beta decay. This surprising result overturned long-held assumptions about parity and the weak force. In recognition of their theoretical work, Lee and Yang were awarded the Nobel Prize for Physics in 1957. However Wu, who was female, was not awarded the Nobel prize.
== History == Spontaneous vertebral artery dissection was described in the 1970s. Prior to this, there had been isolated case reports about carotid dissection. In 1971, C. Miller Fisher, a Canadian neurologist and stroke physician working at Massachusetts General Hospital, first noted the "string sign" abnormality in carotid arteries on cerebral angiograms of stroke patients, and subsequently discovered that the same abnormality could occur in the vertebral arteries. He reported the discovery in a paper in 1978.
In 1930 Ochoa returned to Madrid to complete research for his MD thesis, which he defended that year. In 1931, a newly minted MD, he married Carmen García Cobián. They did not have any children. He then began postdoctoral study at the National Institute for Medical Research in London, where he worked with Henry Hallett Dale. His London research involved the enzyme glyoxalase and was an important departure in Ochoa's career in two respects. First, the work marked the beginning of Ochoa's lifelong interest in enzymes. Second, the project was at the cutting edge of the rapidly evolving study of intermediary metabolism.
Sources: en.wikipedia.org
The United States Forces – Iraq (USF-I) was a United States military sub-unified command, part of U.S. Central Command. It was stationed in Iraq as agreed with the Government of Iraq under the U.S.–Iraq Status of Forces Agreement. USF–I replaced the previous commands Multi-National Force – Iraq, Multi-National Corps – Iraq, and Multi-National Security Transition Command – Iraq from January 2010. General Raymond T. Odierno initially served as commanding general but he was replaced by General Lloyd Austin in September of 2010. The logo of the USF-I depicts a lamassu. As of May 2011, all non-U.S. coalition members had withdrawn from Iraq. The vast majority of Department of Defense personnel then withdrew by 18 December 2011. Only 147 DOD personnel remained at the Embassy of the United States, Baghdad.
==== 1.C Pore-forming toxins (proteins and peptides) ==== 1.C.3 α-Hemolysin (αHL) family 1.C.4 Aerolysin family 1.C.5 ε-toxin family 1.C.11 RTX-toxin superfamily 1.C.12 Membrane attack complex/perforin superfamily 1.C.13 Leukocidin family 1.C.14 Cytohemolysin (CHL) family 1.C.39 Thiol-activated cholesterol-dependent cytolysin family 1.C.43 Lysenin family 1.C.56 Pseudomonas syringae HrpZ cation channel family 1.C.57 Clostridial cytotoxin family 1.C.58 The Microcin E492/C24 (Microcin E492) Family 1.C.74 Snake cytotoxin (SCT) family 1.C.97 Pleurotolysin pore-forming family
== Investigation == Mendonça's tutor called his parents because the child had not turned up for his 5:00 PM lesson, and they quickly initiated a search for him. Because Mendonça had told his mother that he was planning to meet up with his friend Dias, the police sought him for questioning. Dias was in an emotional state while being questioned, and simply replied that he did not know the boy's whereabouts, but that the police "should close the borders". Dias was interrogated by the police. Mendonça's cousin, João André Mendonça, recounted to the police that he, Mendonça and Dias had had a conversation where Dias had invited them to go meet up with a prostitute. The cousin said he had not joined Mendonça and Dias that afternoon because his mother would not let him leave the house. The police considered the possibility of kidnapping, slavery, homicide and suicide.
== Treatment == Ciguatera poisoning is a treatable condition. Genetically susceptible individuals can develop a long-term illness due to inability to clear the Ciguatera toxins; these people can be treated using the protocol for Chronic Inflammatory Response Syndrome (CIRS). Acutely, the mainstay of treatment is supportive care, but once the toxin is identified, CIRS treatment should start as soon as possible, as it will speed recovery, even for those without the genetic susceptibility. There is some evidence that calcium channel blockers like nifedipine and verapamil are effective in treating some of the symptoms that remain after the initial sickness passes, such as poor circulation and shooting pains through the chest. These symptoms are due to vasoconstriction caused by maitotoxin and/or palytoxin. Ciguatoxin lowers the threshold for opening voltage-gated sodium channels in synapses of the nervous system. Opening a sodium channel causes depolarization, which could sequentially cause paralysis, vasoconstriction, and changing the senses of hot and cold. Some medications such as amitriptyline may reduce some symptoms, such as fatigue and paresthesia, although benefit does not occur in every case.
Sources: en.wikipedia.org
No. Thymosin beta-4 is a 43-residue natural peptide, while TB-500 is a commercial label applied to a short synthetic fragment of it. The two differ in length, sequence coverage and how they are handled in the laboratory.
Published work usually examines actin binding, cell migration and tissue repair endpoints in cell and animal models. Findings are generally described as preliminary, and controlled human data remain limited.
Because TB-500 is a trade name rather than a chemical identifier, different vendors and papers may attach it to different fragment lengths. Checking the stated sequence is the practical way to resolve the ambiguity.
The dry powder is normally kept at -20 °C, protected from light and moisture. Reconstituted solutions are often divided into aliquots and stored at -80 °C to reduce freeze-thaw damage.